46.33
前日終値:
$46.76
開ける:
$46.35
24時間の取引高:
573.67K
Relative Volume:
0.14
時価総額:
$111.46B
収益:
$49.41B
当期純損益:
$5.59B
株価収益率:
19.41
EPS:
2.3875
ネットキャッシュフロー:
$8.32B
1週間 パフォーマンス:
-2.72%
1か月 パフォーマンス:
+6.20%
6か月 パフォーマンス:
-5.11%
1年 パフォーマンス:
-10.09%
Sanofi Adr Stock (SNY) Company Profile
Compare SNY vs LLY, JNJ, ABBV, AZN, MRK
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
SNY
Sanofi Adr
|
46.33 | 112.51B | 49.41B | 5.59B | 8.32B | 2.3875 |
|
LLY
Lilly Eli Co
|
934.37 | 839.28B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
236.68 | 574.36B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
205.14 | 367.80B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
201.93 | 316.42B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
MRK
Merck Co Inc
|
119.84 | 299.89B | 64.93B | 18.26B | 12.36B | 7.2751 |
Sanofi Adr Stock (SNY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-12 | ダウングレード | BofA Securities | Buy → Neutral |
| 2026-01-27 | 開始されました | Citigroup | Neutral |
| 2026-01-16 | ダウングレード | UBS | Buy → Neutral |
| 2026-01-06 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2025-12-09 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-12-08 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2025-09-08 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-09-02 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-08-08 | アップグレード | JP Morgan | Neutral → Overweight |
| 2025-04-15 | 開始されました | Exane BNP Paribas | Outperform |
| 2025-03-21 | 開始されました | Goldman | Neutral |
| 2025-01-30 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-07-26 | 繰り返されました | Argus | Buy |
| 2024-01-23 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-01-16 | 再開されました | UBS | Buy |
| 2023-12-05 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2023-10-30 | ダウングレード | Stifel | Buy → Hold |
| 2023-09-06 | アップグレード | Berenberg | Hold → Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-04-28 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2023-03-27 | アップグレード | Barclays | Equal Weight → Overweight |
| 2022-12-13 | 再開されました | Morgan Stanley | Overweight |
| 2022-08-12 | アップグレード | Deutsche Bank | Sell → Hold |
| 2022-08-09 | ダウングレード | UBS | Buy → Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2021-09-27 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-01-15 | 開始されました | Deutsche Bank | Sell |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-03-17 | アップグレード | Barclays | Underweight → Equal Weight |
| 2020-03-11 | アップグレード | Goldman | Neutral → Buy |
| 2020-02-11 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-01-06 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-09-23 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-09-20 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-09-03 | 開始されました | Bernstein | Outperform |
| 2019-08-14 | アップグレード | UBS | Neutral → Buy |
| 2018-12-11 | アップグレード | Jefferies | Hold → Buy |
| 2018-11-01 | アップグレード | Barclays | Underweight → Equal Weight |
| 2018-10-09 | 開始されました | Guggenheim | Neutral |
| 2018-09-10 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2018-08-10 | アップグレード | Citigroup | Neutral → Buy |
| 2018-03-23 | アップグレード | Liberum | Hold → Buy |
| 2018-01-23 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2017-12-06 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2017-12-01 | ダウングレード | Morgan Stanley | Overweight → Underweight |
| 2017-11-15 | アップグレード | Barclays | Underweight → Equal Weight |
| 2017-08-30 | アップグレード | HSBC Securities | Reduce → Hold |
すべてを表示
Sanofi Adr (SNY) 最新ニュース
Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria - GlobeNewswire Inc.
SNY Earnings History & Surprises | EPS & Revenue Results | SANOFI-ADR (NASDAQ:SNY) - ChartMill
Sanofi (SNY) Stock Price, News, Quote & History - Yahoo! Finance Canada
SNY Stock Price, Quote & Chart | SANOFI-ADR (NASDAQ:SNY) - ChartMill
Morgan Stanley lowers Sanofi stock price target on FX update - Investing.com UK
Morgan Stanley lowers Sanofi stock price target on FX update By Investing.com - Investing.com Canada
AstraZeneca Strengthens Position In COPD Race With Successful Trials - Sahm
Sanofi ADR (NASDAQ:SNY) Presents a Classic Value Investment Case - ChartMill
Sanofi S.A. stock faces pressure amid dividend payout and sector headwinds on Euronext Paris - AD HOC NEWS
Medicare Chief Chris Klomp Optimistic On CDC Director Search As Vaccine Fight Roils Agency— 'We Will Select...' - Sahm
Federal Judge Flags Legal Flaws In RFK Jr.'s Vaccine Overhaul - Sahm
Sanofi (NASDAQ:SNY) Emerges as a Top Dividend Stock from Methodical Screening - ChartMill
Dupixent Leads the Charge for Sanofi's Strong Portfolio in Immunology, Vaccines, and Rare Diseases - Morningstar
MRNA Stock Gains After CHMP Endorses COVID-19-Influenza Combo Shot - Finviz
Antibiotics Market - GlobeNewswire Inc.
Sanofi (SNY) and Regeneron's Dupixent Recommended for EU Approval - Finviz
Kymera Q4 Loss Wider Than Expected, Cash Boost Extends Runway - Finviz
DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus - Finviz
Novavax Stock Gains as Q4 Earnings & Sales Beat Estimates - Finviz
How Do Investors Really Feel About Sanofi SA? - Sahm
CYTK Posts a Wider-Than-Expected Q4 Loss, Advances Myqorzo Launch Plans - Finviz
BMRN Beats on Q4 Earnings, to Withdraw Roctavian From Market - Finviz
Sanofi's (SNY) R&D Track Record Remains Investor Concern, Says BofA - Finviz
Manuela Buxo To Become Head of Sanofi's (SNY) Specialty Care Global Business Unit - Finviz
Teva And Sanofi Duvakitug Data Support IBD Pipeline And Growth Story - Sahm
Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease - Sahm
RIGL Stock Rises 59% in a Year: Time to Buy, Hold or Sell? - Finviz
SNY Stock Falls After Board Suddenly Makes Leadership Change - Finviz
Sanofi Pulls the Emergency Brake: What the Hudson Ouster and Garijo Appointment Really Mean for Investors - CTOL Digital Solutions
Should Investors Buy, Sell or Hold Amicus Stock Ahead of Q4 Earnings? - Finviz
SNY's Rare Disease Drug Wins FDA Breakthrough and Japan Orphan Status - Finviz
Sanofi Adr (SNY) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):